Polypectomy and Local Resections of the Colorectum Structured Pathology Reporting Proforma

Similar documents
Colorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY

Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma

Vulva Cancer Histopathology Reporting Proforma

Imaging Evaluation of Polyps. CT Colonography: Sessile Adenoma. Polyps, DALMs & Megacolon Objectives

LOINC. Clinical information. RCPA code. Record if different to report header Operating surgeon name and contact details. Absent.

Gastric Cancer Histopathology Reporting Proforma

Colonic Polyp. Najmeh Aletaha. MD

Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines

Surveying the Colon; Polyps and Advances in Polypectomy

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type

S1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles

05/07/2018. Organisation. The English screening programme what is happening? Organisation. Bowel cancer screening in the UK is:

Colon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition

Hyperplastische Polyps Innocent bystanders?

Carcinoma of the Renal Pelvis and Ureter Histopathology

Patologia sistematica V Gastroenterologia Prof. Stefano Fiorucci. Colon polyps. Colorectal cancer

Colon and Rectum: 2018 Solid Tumor Rules

Emerging Interventions in Endoscopy. Margaret Vance Nurse Consultant in Gastroenterology St Mark s Hospital

Pathology in Slovenian CRC screening programme:

Update on Colonic Serrated (and Conventional) Adenomatous Polyps

Neoplastic Colon Polyps. Joyce Au SUNY Downstate Grand Rounds, October 18, 2012

FNA Thyroid Cytology Structured Reporting Proforma

Sentinel nodes. Location: Location: S1.04 Principal clinician. G1.01 Record other relevant information. S2.01 Number of specimens submitted

Small Intestine. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition

Carcinoma of the Urinary Bladder Histopathology

Appendix 4: WHO Classification of Tumours of the pancreas 17

European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition

Colorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.

Gastric Polyps. Bible class

Pathology in Slovenian CRC screening programme: Organisation and quality assurance. Snježana Frković Grazio and Matej Bračko

Colon Cancer Screening & Surveillance. Amit Patel, MD PGY-4 GI Fellow

Serrated Polyps and a Classification of Colorectal Cancer

S1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES

OPEN ACCESS TEXTBOOK OF GENERAL SURGERY

Quality assurance in pathology in colorectal cancer screening and diagnosis European recommendations

Douglas K. Rex, MD Indiana University Hospital Indianapolis, IN

malignant polyp Daily Challenges in Digestive Endoscopy for Endoscopists and Endoscopy Nurses BSGIE Annual Meeting 18/09/2014 Mechelen

removal of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2

General Surgery Grand Grounds

colorectal cancer Colorectal cancer hereditary sporadic Familial 1/12/2018

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Large Colorectal Adenomas An Approach to Pathologic Evaluation

Management of pt1 polyps. Maria Pellise

COLON AND RECTUM SOLID TUMOR RULES ABSTRACTORS TRAINING

FINAL HISTOLOGICAL DIAGNOSIS: Villo-adenomatous polyp with in-situ-carcinomatous foci (involving both adenomatous and villous component).

The malignant colorectal polyp

Screening & Surveillance Guidelines

Arzu Ensari, MD, PhD Department of Pathology Ankara University Medical School

General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer

Endoscopic Corner CASE 1. Kimtrakool S Aniwan S Linlawan S Muangpaisarn P Sallapant S Rerknimitr R

Colorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi

Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care

2007 Multiple Primary and

Hereditary Gastric Cancer

PATHOLOGY GROUP GUIDELINES FOR THE EXAMINATION AND REPORTING OF COLORECTAL CANCER SPECIMENS

8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank

CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING

Colon Polyps: Detection, Inspection and Characteristics

11/21/13 CEA: 1.7 WNL

5/2/2018. Low Grade Dysplasia of GI Tract. High Grade Dysplasia of GI Tract. Dysplasia in Gastrointestinal Tract: Practical Pearls and Issues

Colorectal carcinoma: Pathologic aspects

Polypoid lesions of the gastrointestinal tract

Colon Screening in 2014 Offering Patients a Choice. Clark A Harrison MD The Nevada Colon Cancer Partnership

Dysplasia 4/19/2017. How do I practice Chromoendoscopy for Surveillance of Colitis? SCENIC: Polypoid Dysplasia in UC. Background

*OPERATIVE PROCEDURE. Serum tumour markers within normal limits S1.04 PRINCIPAL CLINICIAN

Gastrointestinal Malignancies. Dr Rodney ITAKI Pathology Division, SMHS, UPNG Anatomical Pathology Discipline

Razvan I. Arsenescu, MD Assistant Professor of Medicine Division of Digestive Diseases EARLY DETECTION OF COLORECTAL CANCER

EARLY DETECTION OF COLORECTAL CANCER. Epidemiology of CRC

what is the alternative mechanism of histogenesis? Aspects of the morphology of the adenomacarcinoma Morphology of the

Adenoma and Malignant Colorectal Polyp: Pathological Considerations and Clinical Applications

When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool

Serrated Lesions in the Bowel Cancer Screening Programme

References. GI Biopsies. What Should Pathologists Assistants Know About Gastrointestinal Histopathology? James M Crawford, MD, PhD

COLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION.

Sessile Serrated Polyps

MVST BOD & NST PART IB Thurs. 2 nd & Fri. 3 rd March 2017 Pathology Practical Class 23

Clinical UM Guideline

Objectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background

Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population

Colon Cancer Screening. Layth Al-Jashaami, MD GI Fellow, PGY 4

Tumors of the Intestines. Malignant Lesion. Adenocarcinoma. sessile Serrated Adenomas

What Pathology can tell us in the approach of localized colorectal cancer

Morphologic Criteria of Invasive Colonic Adenocarcinoma on Biopsy Specimens

Quality Measures In Colonoscopy: Why Should I Care?

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

Summary. Cezary ŁozińskiABDF, Witold KyclerABCDEF. Rep Pract Oncol Radiother, 2007; 12(4):

This is the portion of the intestine which lies between the small intestine and the outlet (Anus).

Historical. Note: The parenthetical numbers in the Clinical Indications section refer to the source documents cited in the References Section below.

Malignant colorectal polyps: venous invasion and

General and Colonoscopy Data Collection Form

6 semanas de embarazo. Tubulovillous adenoma with dysplasia icd 10. Inicio / Embarazo / 6 semanas de embarazo

LIST OF ABBREVIATIONS

BSG/TSL GI workshops EQA011 preliminary response analysis

BSG/TSL GI workshops EQA011 final response analysis with diagnoses

Synchronous and Subsequent Lesions of Serrated Adenomas and Tubular Adenomas of the Colorectum

Seventh Edition Staging 2017 Colorectum. Overview. This webinar is sponsored by. the Centers for Disease Control and Prevention.

The Importance of Complete Colonoscopy and Exploration of the Cecal Region

Bowel obstruction and tumors

Measure #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clincal Care

Update on staging colorectal carcinoma, the 8 th edition AJCC. General overview of staging. When is staging required? 11/1/2017

Transcription:

Polypectomy and Local Resections of the Colorectum Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth DD MM YYYY S1.02 Clinical details Male Female Intersex/indeterminate Patient identifiers e.g. MRN, IHI or NHI (please indicate which) Date of request S1.03 Accession number Requesting doctor - name and contact details Sex Ethnicity DD MM YYYY Unknown Aboriginal/Torres Strait Islander Other ethnicity: Proceduralists name & contact details Number of specimens submitted Relevant patient or family history Multiple unexcised polyps Reason for procedure Initial screening colonoscopy (baseline or index procedure) Surveillance no previous history of adenoma or malignancy Surveillance high risk eg FAP, other polyposis syndromes, Lynch syndrome Surveillance previous adenoma/hgd/ malignant polyps Date and results of previous episode Previous colorectal surgery Issues noted during procedure G1.01 Other relevant details Positive faecal occult blood test (FOBT) Other (specify) Other specific details recorded in the table overleaf. V0.1 Proforma from Polypectomy and Local Resection of the Colorectum Structured Reporting Protocol 2nd Edition Page 1 of 6

V0.1 Proforma from Polypectomy and Local Resection of the Colorectum Structured Reporting Protocol 2nd Edition Page 2 of 6

Macroscopic findings S2.01 Number of specimens submitted V0.1 Proforma from Polypectomy and Local Resection of the Colorectum Structured Reporting Protocol 2nd Edition Page 3 of 6

S2.05 Dimensions of TEM (if applicable) length x width x thickness G2.03 TEMS SPECIMEN Lesion dimensions length x width x thickness Colour Surface contour Ulceration S2.06 Nature and site of all blocks V0.1 Proforma from Polypectomy and Local Resection of the Colorectum Structured Reporting Protocol 2nd Edition Page 4 of 6

Microscopic findings S3.01 Polyp type Hyperplastic polyp Conventional adenoma o tubular o tubulovillous o villous Serrated adenomas o traditional serrated adenoma (TSA) o sessile serrated adenoma/polyp (SSA) o sessile serrated adenoma with dysplasia (SSAD) Mixed polyp (specify components) Carcinoma Neuroendocrine tumour Hamartoma Inflaatory polyp Juvenile type polyp Mesenchymal polyp fibroblastic polyp (perineurioma), Schwann cell hamartoma, schwannoma, neurofibroma, ganglioneuroma, leiomyoma, lipoma, granular cell tumour, inflaatory fibroid polyp, gastrointestinal stromal tumour Mucosal prolapse syndrome Other (specify) S3.04 Coexistent abnormalities None noted Ulcerative colitis Crohn s disease Primary sclerosing cholangitis (PSC) Inflaatory bowel disease, not otherwise specified Other (specify) Note: If Ulcerative colitis, Crohn s disease, Primary sclerosing cholangitis (PSC) or Inflaatory bowel disease, not otherwise specified is selected the following text may be added to allow clarification of colorectal carcinoma risk Dysplastic lesions arising in an area affected by inflaatory bowel disease are a heterogeneous group. Many are adenoma like, and are not progressive. Conservative management may be warranted if the following conditions are met: Macroscopically adenoma like in appearance; excised with clear margins; no flat dysplasia of surrounding mucosa and/or polyp stalk. If these criteria are not met, the lesion should be regarded as having a significant risk for associated or subsequent colorectal carcinoma. V0.1 Proforma from Polypectomy and Local Resection of the Colorectum Structured Reporting Protocol 2nd Edition Page 5 of 6

MALIGNANT POLYP S3.05 Tumour type Adenocarcinoma, NOS Cribriform comedo-type adenocarcinoma Medullary carcinoma, NOS Micropapillary carcinoma Colloid carcinoma Serrated adenocarcinoma Signet ring cell carcinoma Adenosquamous carcinoma Spindle cell carcinoma, NOS Squamous cell carcinoma, NOS Undifferentiated carcinoma Other S3.10 Maximum depth of invasion Record as the max. depth of invasion beneath the muscularis mucosae or the max. tumour thickness if the muscularis mucosae is destroyed by tumour; or the max. dimension of invasive adenocarcinoma in any piece. Haggit level Level 1 Level 2 Level 3 Level 4 S3.11 Width of invasive tumour G3.05 Coent on risk for residual disease S3.06 Histological tumour grade Low grade well and moderately differentiated High grade poorly and undifferentiated S3.07 Poor differentiation (undifferentiated) tumour G3.03 Tumour budding S3.08 Vessel invasion Not identified Ancillary test findings G4.01 Mismatch repair enzymes MLH-1 PMS-2 MSH-2 MSH-6 Not tested Normal staining Loss of staining S3.09 Margin status Coents Not involved Involved Clearance from deep margin Clearance from nearest peripheral margin G4.03 Special stains Involved margin(s) Synthesis and overview G5.01 Diagnostic suary G3.04 Morphology Pedunculated Sessile Indeterminate S5.01 Overarching coent V0.1 Proforma from Polypectomy and Local Resection of the Colorectum Structured Reporting Protocol 2nd Edition Page 6 of 6